1. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.
- Author
-
Ghosal S, Das S, Pang Y, Gonzales MK, Huynh TT, Yang Y, Taieb D, Crona J, Shankavaram UT, and Pacak K
- Subjects
- Adrenal Gland Neoplasms metabolism, Adrenal Gland Neoplasms pathology, Biomarkers, Tumor biosynthesis, Biomarkers, Tumor genetics, Humans, Neoplasm Metastasis, Neuroendocrine Tumors metabolism, Neuroendocrine Tumors pathology, Paraganglioma metabolism, Paraganglioma pathology, Pheochromocytoma metabolism, Pheochromocytoma pathology, Prognosis, Progression-Free Survival, RNA, Neoplasm biosynthesis, RNA, Neoplasm genetics, RNA, Untranslated biosynthesis, Transcriptome, Adrenal Gland Neoplasms genetics, Neuroendocrine Tumors genetics, Paraganglioma genetics, Pheochromocytoma genetics, RNA, Untranslated genetics
- Abstract
Many long intergenic noncoding RNAs (lincRNAs) serve as cancer biomarkers for diagnosis or prognostication. To understand the role of lincRNAs in the rare neuroendocrine tumors pheochromocytoma and paraganglioma (PCPG), we performed first time in-depth characterization of lincRNA expression profiles and correlated findings to clinical outcomes of the disease. RNA-Seq data from patients with PCPGs and 17 other tumor types from The Cancer Genome Atlas and other published sources were obtained. Differential expression analysis and a machine-learning model were used to identify transcripts specific to PCPGs, as well as established PCPG molecular subtypes. Similarly, lincRNAs specific to aggressive PCPGs were identified, and univariate and multivariate analysis was performed for metastasis-free survival. The results were validated in independent samples using RT-PCR. From a pan-cancer context, PCPGs had a specific and unique lincRNA profile. Among PCPGs, five different molecular subtypes were identified corresponding to the established molecular classification. Upregulation of 13 lincRNAs was found to be associated with aggressive/metastatic PCPGs. RT-PCR validation confirmed the overexpression of four lincRNAs in metastatic compared to non-metastatic PCPGs. Kaplan-Meier analysis identified five lincRNAs as prognostic markers for metastasis-free survival of patients in three subtypes of PCPGs. Stratification of PCPG patients with a risk-score formulated using multivariate analysis of lincRNA expression profiles, presence of key driver mutations, tumor location, and hormone secretion profiles showed significant differences in metastasis-free survival. PCPGs thus exhibit a specific lincRNA expression profile that also corresponds to the established molecular subgroups and can be potential marker for the aggressive/metastatic PCPGs., (© 2019 UICC.)
- Published
- 2020
- Full Text
- View/download PDF